IDiyas

For the Inventor, By the Inventor

London, United Kingdom

William L Mitchell

USPTO Granted Patents = 16

Average Co-Inventor Count = 5.1

ph-index = 10

Forward Citations = 179(Granted Patents)


Location History:

  • London, GB (1989 - 1994)
  • Ware, GB (1996)
  • Herts, GB (1999)
  • Welwyn, GB (2009)
  • Harlow, GB (2009)

Company Filing History:

goldMedal16 out of 1,168 
 
Glaxo Group Limited
 patents

Years Active: 1989-2009

Loading Chart...
16 patents (USPTO):Explore Patents
1. 7635701 - Pyrimidine derivatives and their use as CB2 modulators (2009-12-22),
2. 7589206 - Pyrrolopyridine derivatives (2009-09-15),
3. 5861414 - Piperidineacetic acid derivatives useful as fibrinogen antagonist agent (1999-01-19),
4. 5510350 - Benzanilide derivatives (1996-04-23),
5. 5283262 - Phenethanolamine derivatives (1994-02-01),
6. 5202343 - Tricyclic ketones useful as HT.sub.3 -receptor antagonists (1993-04-13),
7. 5109023 - Phenethanolamine derivatives (1992-04-28),
8. 5099068 - Phenethanolamine derivatives (1992-03-24),
9. 5066678 - Phenethandamine derivatives and pharmaceutical use thereof (1991-11-19),
10. 5045545 - [(Imidazol-4(and 5)-yl)methyl] tetracyclic ketones having 5-HT.sub.3 (1991-09-03),
11. 4997986 - Phenethanolamine derivatives (1991-03-05),
12. 4950681 - Ketone derivatives (1990-08-21),
13. 4939144 - Tricyclic ketone derivatives as 5-HT antagonists (1990-07-03),
14. 4937268 - Chemical compounds (1990-06-26),
15. 4859662 - Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating (1989-08-22),

Title: William L. Mitchell: Pioneer in Drug Development

Introduction

William L. Mitchell, a notable inventor based in London, GB, has made significant contributions to pharmaceutical innovation. With a total of 16 patents to his name, he has focused his research on developing novel compounds with therapeutic applications, particularly in the realm of pain management.

Latest Patents

Among his most recent inventions are:

1. **Pyrimidine Derivatives and Their Use as CB2 Modulators** - This invention relates to innovative pyrimidine derivatives and their pharmaceutical compositions. These compounds are designed to treat diseases caused by the modulation of the cannabinoid receptor, focusing primarily on pain-related conditions.

2. **Pyrrolopyridine Derivatives** - Similar to his work on pyrimidine derivatives, this invention introduces novel pyrrolopyridine derivatives. These pharmaceutical compositions also aim to address diseases linked to cannabinoid receptor activity, again spotlighting pain management.

Career Highlights

William L. Mitchell's work is primarily associated with Glaxo Group Limited, a leading pharmaceutical company. His research has been instrumental in understanding cannabinoid receptors and their therapeutic potential, paving the way for new pain management therapies.

Collaborations

Throughout his career, Mitchell has collaborated with other esteemed professionals in the field, including Alan Naylor and Ian F. Skidmore. These collaborations have enhanced the depth and breadth of his research, contributing to his successful patent portfolio.

Conclusion

William L. Mitchell has firmly established himself as a key inventor in the pharmaceutical industry. His innovative work on pyrimidine and pyrrolopyridine derivatives reflects a commitment to improving patient outcomes in pain management. As research in cannabinoid receptors continues to evolve, Mitchell's contributions will undoubtedly remain significant in the advancement of medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…